Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more

COUR Pharmaceutical Development Company, Inc.NCT06106672